Delivery Order SPE2DB22D1106-SPE2DB25FFDA1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,031.38 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (120 mL) on August 13, 2025, with an ultimate completion date of August 14, 2025. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,283.02 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of July 31, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $3,154.08 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement action typical of DLA's ongoing medical...
- The Defense Logistics Agency awarded a $2,566.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), with an ultimate completion date of August 4, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, valued at $1,082.52 under a firm fixed-price contract. This delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $2,544.36 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 11, 2025. The product will be sourced from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) valued at $1,740.04 under a firm fixed-price contract type. This delivery order, which has an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 60 mL quantity, with a ceiling value of $1,968.69. This is a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,051.36 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. This competitively awarded, firm fixed-price delivery order is not set-aside and represents performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract operates under AmerisourceBergen Drug Corp's existing...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $3,527.50 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (120 mL) on August 5, 2025, with completion targeted for August 6, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. The product will be performed at AmerisourceBergen's corporate office...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFDA1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,198.09 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. The contract, executed on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a firm fixed price delivery order with no set-aside designation. This award was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The product will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The SPE2DX vehicle through which this order was placed is a comprehensive global pharmaceutical support contract that enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive capability in delivering both brand-name and generic medications across multiple therapeutic domains, positioning it as a key provider within the Defense Logistics Agency's Medical Supply Chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 8/13/25 |